Of counsel
James Baillieu explores the pharma M&A horizon in
PharmaTimes magazine. The pharma sector saw deal activity fall
in 2017 compared to previous years. While the number of deals
remained robust, their value was significantly lower due to fewer
large acquisitions. Looking ahead, however, many expect deal levels
to pick-up as Trump's tax reforms give US companies increased
cash resources to fund acquisitions. Indeed, as of mid-January
deals worth over $30 billion have already been announced.
Please
check out the article in PharmaTimes for more.
About Norton Rose Fulbright Canada LLP
Norton Rose Fulbright is a global law firm. We provide the
world's preeminent corporations and financial institutions with
a full business law service. We have 3800 lawyers and other legal
staff based in more than 50 cities across Europe, the United
States, Canada, Latin America, Asia, Australia, Africa, the Middle
East and Central Asia.